Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03332355
Title Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vanquish Oncology, Inc.
Indications

malignant astrocytoma

glioblastoma

lymphoma

Advanced Solid Tumor

Therapies

PAC-1 + Temozolomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.